Table 8. Analysis of combination of the tests evaluated over 53 active pulmonary TB patients and 82 HCA being concomitantly tested and stratified by HIV status.
| Positive over total tested. Percentage (95% CI) | Negative over total tested. Percentage (95% CI) | |||||||||||||
| Sensitivity | Specificity | |||||||||||||
| TST | QFT-IT | SM | QFT-GITwith TST | SMwith TST | SM withQFT-GIT | QFT-GITwith TSTwith SM | P Value* | TST | QFT-IT | SM | QFT-GITwith TST | QFT-GITwith TSTand SM | p value * | |
| HIV-infected | 17/33. 51.5 (33.5–69.2) | 22/33. 66.7 (48.2–82.0) | 15/33. 45.5 (28.1–63.7) | 24/33. 72.7 (54.5–86.7) | 24/33. 72.7 (54.5–86.7) | 28/33. 84.9 (68.1–94.9) | 28/33. 84.9 (68.1–94.9) | 0.0016 | 45/54. 83.3 (70.7–92.1) | 35/54 64.8 (50.6–77.3) | 0/54 100 (93.4–100) | 34/54 63.0 (48.7–75.7) | 34/54 63.0 (48.7–75.7) | <0.0001 |
| HIV-uninfected | 17/20 85.0 (62.1–96.8) | 19/20 95.0 (75.1–99.9) | 16/20 80 (56.3–94.3) | 20/20 100 (83.2–100) | 19/20 95.0 (73.1–99.8) | 19/20 95.0 (73.1–99.8) | 20/20 100 (83.2–100) | 0.1111 | 16/12 57.1 (37.2–75.5) | 7/28 25.0 (10.7–44.9) | 0/28 100 (79.4–100) | 6/28 21.4 (8.3–41.0) | 6/28 21.4 (8.3–41.0) | <0.0001 |
| Total | 34/53 64.2 (49.8–76.9) | 41/53 77.4 (63.8–87.7) | 31/53 58.5 (44.1–71.9) | 44/53 83.0 (70.2–91.9) | 43/53 81.1 (68.0–90.6) | 47/53 88.7 (77.0–95.7) | 48/53 90.6 (79.4–96.9) | 0.0002 | 61/82 74.4 (63.3–82.4) | 42–82 51.2 (39.9–62.4) | 0/82 100 (88.8–100) | 40/82 48.8 (37.6–60.1) | 40/82 48.8 (37.6–60.1) | <0.0001 |
Footnotes: HIV: human immunodeficiency virus; TB: tuberculosis; TST: Tuberculin skin test; HCA: healthy community adults; QFT-GIT: QuantiFERON® Gold in Tube (indeterminate results included as negative results); SM: smear microscopy.
*
X square test was used for statistical analysis.